Freestone Capital Holdings LLC Takes Position in BioNTech SE Sponsored ADR $BNTX

Freestone Capital Holdings LLC acquired a new stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,914 shares of the company’s stock, valued at approximately $753,000.

A number of other hedge funds have also bought and sold shares of the business. Banque Pictet & Cie SA increased its position in BioNTech by 12.6% during the fourth quarter. Banque Pictet & Cie SA now owns 21,735 shares of the company’s stock worth $2,069,000 after acquiring an additional 2,424 shares during the period. SG Americas Securities LLC increased its position in BioNTech by 1,664.6% during the fourth quarter. SG Americas Securities LLC now owns 365,333 shares of the company’s stock worth $34,780,000 after acquiring an additional 344,630 shares during the period. Arlington Capital Management Inc. bought a new position in BioNTech during the fourth quarter worth about $248,000. Hudson Bay Capital Management LP increased its position in BioNTech by 36.7% during the third quarter. Hudson Bay Capital Management LP now owns 205,004 shares of the company’s stock worth $20,217,000 after acquiring an additional 55,004 shares during the period. Finally, Krensavage Asset Management LLC increased its position in BioNTech by 8.2% during the third quarter. Krensavage Asset Management LLC now owns 79,366 shares of the company’s stock worth $7,827,000 after acquiring an additional 5,984 shares during the period. 15.52% of the stock is owned by institutional investors.

BioNTech Stock Performance

Shares of BioNTech stock opened at $98.41 on Wednesday. The company has a 50 day moving average of $98.37 and a 200-day moving average of $101.04. BioNTech SE Sponsored ADR has a 1-year low of $79.52 and a 1-year high of $124.00. The company has a current ratio of 7.54, a quick ratio of 7.49 and a debt-to-equity ratio of 0.01. The company has a market cap of $24.89 billion, a PE ratio of -18.78 and a beta of 1.58.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Saturday, February 14th. The company reported ($0.39) earnings per share for the quarter. BioNTech had a negative return on equity of 4.76% and a negative net margin of 38.09%.The firm had revenue of $1.06 billion for the quarter. As a group, equities research analysts forecast that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on BNTX shares. Canaccord Genuity Group reaffirmed a “buy” rating and set a $171.00 price target on shares of BioNTech in a research report on Wednesday, March 11th. Truist Financial raised shares of BioNTech to a “strong-buy” rating in a research report on Wednesday, March 25th. Jefferies Financial Group reaffirmed a “buy” rating on shares of BioNTech in a research report on Wednesday, March 25th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of BioNTech in a research report on Wednesday, March 11th. Finally, Berenberg Bank reaffirmed a “buy” rating on shares of BioNTech in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, BioNTech presently has a consensus rating of “Moderate Buy” and an average target price of $133.13.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.